Inflammation / NLRP3 / Pyroptosis / Complement

Sources covering the Pipeline of Inflammation arc: NLRP3 structure / toxicity / Tx, NLRP3 inhibitor (Marianthi, PFR-4231-100), CAPS, pyroptosis MOA and assays, inflammasome / interferon / cytokine omics, Complement / C5aR1 (Woodruff), Havrda, In Vivo strategy (Katy), and 4 LPS.

Source-of-truth pages live in data/processed/markdown/by-photo/. Each row below points first to the KB source note (which carries the heading list) and then to the canonical transcription.

Sources in this section: 42

Top-level nav clusters: 19

Pipeline of Inflammation

14 source pages

photopagenav pathsource notetranscription
20240722_183121Page 626 of 632Pipeline of Inflammation > Pyroptosis MOA > Pyroptosis evidence/MOA/Correction in PDnotemd
20240722_183125Page 651 of 660Pipeline of Inflammation > Pyroptosis MOAnotemd
20240722_183128Page 651 of 660Pipeline of Inflammation > Pyroptosis MOA > Pyroptosis evidence/MOAnotemd
20240722_183141Page 661 of 670Pipeline of Inflammation > CAPS > WBC > Dx > ARP > Sxnotemd
20240722_183153Page 661 of 670Pipeline of Inflammation > Pipeline CAPS > Animal model > TM > NLRP3 inhibitor (Marianthi) (PFR-4231-100)notemd
20240722_183206Page 695 of 701Pipeline of Inflammation > Pipeline CAPS > NLRP3 inhibitor (Marianthi) (PFR-4231-100) > AD > Assays of pyroptosisnotemd
20240722_183218Page 698 of 704Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > AD > Chemistry > Clinical > Comp Bio > Competitornotemd
20240722_183231Page 713 of 719Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > In Vivo strategy > Havrda > HED > IHCnotemd
20240722_183244Page 733 of 738Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > Katy > Longitudinal > Metabolomics > Microglial Imagingnotemd
20240722_183255Page 744 of 750Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > Microglial Imaging > NHP > PDE > PE > PETnotemd
20240722_183308Page 747 of 753Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > PK/PD > PK/PD Strategy > Postmortem > Proteinanotemd
20240722_183321Page 765 of 776Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > Reactome > Safety > Screening flow > ShareFoldernotemd
20240722_183335Page 782 of 789Pipeline of Inflammation > Complement / C5aR1 > MOA > Woodruff’s study plan > Screening > DDnotemd
20240722_183348Page 792 of 798Pipeline of Inflammation > Postmortem > Imaging of Iron > IT > Jayanotemd

Inflammation

5 source pages

photopagenav pathsource notetranscription
20240722_183147Page 661 of 670Inflammation > NLRP3 > Txnotemd
20240722_183159Page 661 of 670Inflammation > NLRP3 inhibitor (Marianthi) > AD > Assays of pyroptosisnotemd
20240722_183225Page 713 of 719Inflammation > Competitor > Havrdanotemd
20240722_183238Page 726 of 732Inflammation > In Vivo strategy > Katynotemd
20240722_184357Page 1036 of 1044Inflammation > 기타 MOA들 > Pittsburgh University > Greenamyre Labnotemd

Assays of pyroptosis

2 source pages

photopagenav pathsource notetranscription
20240722_183203Page 695 of 701Assays of pyroptosisnotemd
20240722_183208Page 698 of 704Assays of pyroptosis > Budget & FTE > Ceri > Chemistrynotemd

Imaging neuroinflammation

2 source pages

photopagenav pathsource notetranscription
20240722_183104Page 626 of 632Imaging neuroinflammationnotemd
20240722_183108Page 626 of 632Imaging neuroinflammation > DPA714 > 3rd Generation TSPOnotemd

In Vivo strategy

2 source pages

photopagenav pathsource notetranscription
20240722_183234Page 713 of 719In Vivo strategy > Katynotemd
20240722_183241Page 726 of 732In Vivo strategy > Katy > Longitudinalnotemd

NLRP3

2 source pages

photopagenav pathsource notetranscription
20240722_183132Page 661 of 670NLRP3 > Structurenotemd
20240722_183144Page 661 of 670NLRP3 > Toxicitynotemd

NLRP3 inhibitor (Marianthi) (P…)

2 source pages

photopagenav pathsource notetranscription
20240722_183156Page 661 of 670NLRP3 inhibitor (Marianthi) (P…) > AD > Assays of pyroptosisnotemd
20240722_183222NLRP3 inhibitor (Marianthi) (P…) > Pipeline / Competitorsnotemd

Stratification strategy on…

2 source pages

photopagenav pathsource notetranscription
20240722_183521Page 882 of 889Stratification strategy on…notemd
20240722_184310Page 984 of 994Stratification strategy on… > Pathogenicity of variantnotemd

[GT]

1 source page

photopagenav pathsource notetranscription
20240722_184743Page 1256 of 1262[GT] > AAV > Capsid (serotype)notemd

Assays of pyroptosis (cytokine / chemokine omics)

1 source page

photopagenav pathsource notetranscription
20240722_183215Page 698 of 704Assays of pyroptosis (cytokine / chemokine omics) > ADnotemd

Background

1 source page

photopagenav pathsource notetranscription
20240722_183342Page 788 of 796Background > Pipeline C5aR1 > Innomedica (Haven) > In Vivo Clibrationnotemd

Comp Bio

1 source page

photopagenav pathsource notetranscription
20240722_183212Page 698 of 704Comp Bionotemd

Cryopyrin-Associated Periodic Syndromes (CAPS)

1 source page

photopagenav pathsource notetranscription
20240722_183138Page 661 of 670Cryopyrin-Associated Periodic Syndromes (CAPS)notemd

Havrda

1 source page

photopagenav pathsource notetranscription
20240722_183228Page 713 of 719Havrdanotemd

Minee Choi

1 source page

photopagenav pathsource notetranscription
20240722_183354Page 798 of 805Minee Choi > Kv1.3 > Kyoko Yoshikawa > Lee Jonghunnotemd

Pipeline CAPS

1 source page

photopagenav pathsource notetranscription
20240722_183150Page 661 of 670Pipeline CAPSnotemd

Pyroptosis evidence/MOA…

1 source page

photopagenav pathsource notetranscription
20240722_183351Page 798 of 805Pyroptosis evidence/MOA…notemd

Pyroptosis MOA

1 source page

photopagenav pathsource notetranscription
20240722_183118Page 626 of 632Pyroptosis MOAnotemd

Stratification strategy on neuroinflammation

1 source page

photopagenav pathsource notetranscription
20240722_183332Page 779 of 784Stratification strategy on neuroinflammation > RNA-Seq (Daria) > C5aR1 (Woodruff, Univ of Queensland)notemd

Cross-References